Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.710
-0.270 (-9.06%)
At close: Dec 20, 2024, 4:00 PM
2.660
-0.050 (-1.85%)
After-hours: Dec 20, 2024, 4:30 PM EST
Daré Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 1.88 | 2.81 | 10 | - | - | - | |
| Revenue Growth (YoY) | 88.13% | -71.92% | - | - | - | - | |
| Cost of Revenue | 21.65 | 21.64 | 30.14 | 0.1 | 0.08 | 0.53 | |
| Gross Profit | -19.76 | -18.83 | -20.14 | -0.1 | -0.08 | -0.53 | |
| Selling, General & Admin | 10.11 | 11.91 | 11.24 | 8.35 | 6.55 | 5.27 | |
| Research & Development | -6.84 | - | - | 30.62 | 20.77 | 8.55 | |
| Operating Expenses | 3.27 | 11.91 | 11.24 | 38.97 | 27.32 | 13.81 | |
| Operating Income | -23.03 | -30.74 | -31.39 | -39.07 | -27.4 | -14.34 | |
| Other Non Operating Income (Expenses) | 20.23 | 0.78 | 0.44 | 0 | 0 | 0.08 | |
| EBT Excluding Unusual Items | -2.8 | -29.96 | -30.95 | -39.07 | -27.4 | -14.26 | |
| Other Unusual Items | -0.4 | -0.4 | - | 0.37 | - | - | |
| Pretax Income | -3.6 | -30.16 | -30.95 | -38.7 | -27.4 | -14.26 | |
| Net Income | -3.6 | -30.16 | -30.95 | -38.7 | -27.4 | -14.26 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.01 | 0.79 | |
| Net Income to Common | -3.6 | -30.16 | -30.95 | -38.7 | -27.41 | -15.05 | |
| Shares Outstanding (Basic) | 8 | 7 | 7 | 5 | 3 | 1 | |
| Shares Outstanding (Diluted) | 8 | 7 | 7 | 5 | 3 | 1 | |
| Shares Change (YoY) | 16.28% | 3.23% | 38.29% | 103.23% | 93.15% | 45.16% | |
| EPS (Basic) | -0.43 | -4.15 | -4.39 | -7.59 | -10.93 | -11.60 | |
| EPS (Diluted) | -0.43 | -4.15 | -4.39 | -7.59 | -10.93 | -11.60 | |
| Free Cash Flow | -8.63 | -39.49 | -18.15 | -28.78 | -25.25 | -13.32 | |
| Free Cash Flow Per Share | -1.04 | -5.43 | -2.58 | -5.65 | -10.07 | -10.26 | |
| Gross Margin | - | - | -201.42% | - | - | - | |
| Operating Margin | -1224.40% | -1094.77% | -313.85% | - | - | - | |
| Profit Margin | -191.61% | -1074.17% | -309.48% | - | - | - | |
| Free Cash Flow Margin | -458.66% | -1406.26% | -181.51% | - | - | - | |
| EBITDA | -22.99 | -30.7 | -31.36 | -39.04 | -27.36 | -14.33 | |
| D&A For EBITDA | 0.05 | 0.04 | 0.02 | 0.03 | 0.04 | 0.01 | |
| EBIT | -23.03 | -30.74 | -31.39 | -39.07 | -27.4 | -14.34 | |
| Revenue as Reported | 1.88 | 2.81 | 10 | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.